Life Science Instrumentation Market

The global life science instrumentation market is projected to reach USD 92.5 billion by 2031 from USD 63.4  billion in 2025, at a CAGR of 6.5% from 2025 to 2030. The life science instrumentation market is growing due to increased adoption of advanced tools in research and development, expansion in manufacturing for pharma-biopharma companies, greater demand from applied industries, ongoing innovations in next-generation sequencing (NGS) technologies, and the rising prevalence of infectious diseases.

The market remains moderately competitive, with both well-established players and emerging companies competing for market share. As of 2025, the leading companies in the global life science instrumentation market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Waters Corporation (US), Shimadzu Corporation (Japan), Becton, Dickinson and Company (US), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), and Hitachi High-Technologies Corporation (Japan), among others. These companies use strategies like mergers and acquisitions, collaborations, partnerships, and product launches to strengthen their presence and grow their market share.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US) is a leading provider of life science instrumentation, offering comprehensive solutions that include analytical technologies, laboratory automation, and high-performance detection systems. The company’s product range features advanced instruments such as mass spectrometers, liquid and gas chromatographs, electron microscopes, and molecular spectroscopy systems, essential for applications in genomics, proteomics, metabolomics, and cell biology. Through its brands like Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific, the company serves academic research institutions, pharmaceutical and biotechnology firms, and clinical laboratories worldwide. Thermo Fisher invests heavily in R&D to incorporate digital tools, AI, and automation into its instruments, improving precision, reproducibility, and throughput for complex biological analyses. Its strong emphasis on innovation and customer-focused solutions makes it a key driver of scientific progress in life science research and healthcare. The company operates in more than 50 countries across North America, Europe, APAC, and Latin America. Major subsidiaries include Thermo Informatics Asia Pacific Pty Ltd. (Australia), Thermo Measurement Ltd (UK), Thermo Instruments Inc. (Canada), Thermo Ramsey Italia S.r.l. (Italy), Thermo Fisher Scientific LLC (US), and Thermo Life Sciences AB (Sweden), among others. The company has adopted inorganic growth strategies such as acquisitions to strengthen its market position.

Danaher Corporation (US) is a global leader in life science instrumentation, offering a diverse range of analytical and research technologies that foster innovation in biotechnology, pharmaceuticals, and academic research. Through its well-known brands—such as Cytiva, Beckman Coulter Life Sciences, Leica Microsystems, and Molecular Devices—the company provides high-precision instruments for applications like genomics, proteomics, cell analysis, and structural biology. Its solutions include chromatography systems, flow cytometers, centrifuges, microscopes, and molecular imaging platforms, allowing scientists to study complex biological processes with greater accuracy and speed. Danaher focuses on continuous innovation through its proprietary Danaher Business System (DBS), promoting operational excellence and customer-focused development. By increasingly integrating automation, digital workflows, and AI-powered data analysis, the company is improving research efficiency, bioprocess optimization, and clinical translation, positioning itself as a key driver of scientific discovery and healthcare progress worldwide.

Agilent Technologies, Inc. (US) is a leading provider of life science instrumentation and analytical solutions, serving the pharmaceutical, biotechnology, academic, and clinical research sectors. The company’s comprehensive portfolio includes mass spectrometry, liquid and gas chromatography, atomic and molecular spectroscopy, microplate readers, and next-generation sequencing sample preparation systems. These tools are crucial for applications in genomics, proteomics, metabolomics, and biopharmaceutical quality control. Agilent also incorporates advanced software, automation, and digital analytics to deliver end-to-end laboratory workflows that improve precision, throughput, and data integrity. Its instruments are widely used in drug development, disease research, and environmental and food testing. With ongoing investments in R&D and sustainability initiatives, Agilent focuses on advancing precision measurement technologies and life science innovation, enabling scientists and healthcare professionals to gain deeper biological insights and speed up discovery from lab to clinic. The company serves various industries, such as pharmaceutical & biotechnology, chemical & energy, environmental testing labs, and contract manufacturing organizations. Some of its major subsidiaries include Agilent Technologies Australia Pty. Ltd., Agilent Technologies Canada, Inc., Agilent Technologies (Cayman Islands) Ltd., and Agilent Technologies (Shanghai) Company Ltd. (China).

Market Ranking

The global life science instrumentation market is relatively concentrated, with companies: Thermo Fisher Scientific Inc. (US), Agilent Technologies (US), Danaher Corporation (US), Water Corporation (US), and Shimadzu Corporation (Japan)—collectively accounting for approximately 30–35% of the market share. A key driver for Thermo Fisher Scientific, Danaher Corporation, and Shimadzu Corporation in this market is the growing global demand for advanced analytical technologies to support biopharmaceutical research, clinical diagnostics, and precision medicine. Rising investments in proteomics, genomics, and cell-based research are fueling the need for high-performance instruments such as mass spectrometers, chromatographs, and microscopy systems. Thermo Fisher benefits from its extensive product portfolio and integration of digital and automation solutions; Danaher leverages its strong brands and the Danaher Business System (DBS) to foster innovation and operational excellence; while Shimadzu emphasizes precision analytical technologies, sustainability, and expanding its R&D capabilities. Together, these companies are driven by increasing government and private sector funding for life sciences, the shift toward biologics and personalized medicine, and continuous technological advancements that improve sensitivity, accuracy, and throughput in laboratory workflows. The remaining 65–70% of the market is divided among regional and specialized companies, which continue to drive innovation and generate opportunities for startups. Overall, competitive dynamics are influenced by the increasing demand for life science instrumentation solutions.

Related Reports:

Life Science Instrumentation Market by Technology (Spectroscopy, Chromatography, Immunoassay, NGS, PCR, Microscopy), Application (Diagnostic, Clinical), End User (Pharma, Agriculture & Food Industry, Hospital, Diagnostic Lab) - Global Forecasts to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com